» Articles » PMID: 17636123

Structural Basis of Antigenic Escape of a Malaria Vaccine Candidate

Overview
Specialty Science
Date 2007 Jul 20
PMID 17636123
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Antibodies against the malaria vaccine candidate apical membrane antigen-1 (AMA-1) can inhibit invasion of merozoites into RBC, but antigenic diversity can compromise vaccine efficacy. We hypothesize that polymorphic sites located within inhibitory epitopes function as antigenic escape residues (AER). By using an in vitro model of antigenic escape, the inhibitory contribution of 24 polymorphic sites of the 3D7 AMA-1 vaccine was determined. An AER cluster of 13 polymorphisms, located within domain 1, had the highest inhibitory contribution. Within this AER cluster, antibodies primarily targeted five polymorphic residues situated on an alpha-helical loop. A second important AER cluster was localized to domain 2. Domain 3 polymorphisms enhanced the inhibitory contribution of the domain 2 AER cluster. Importantly, the AER clusters could be split, such that chimeras containing domain 1 of FVO and domain 2 + 3 of 3D7 generated antisera that showed similarly high level inhibition of the two vaccine strains. Antibodies to this chimeric protein also inhibited unrelated strains of the parasite. Interstrain AER chimeras can be a way to incorporate inhibitory epitopes of two AMA-1 strains into a single protein. The AER clusters map in close proximity to conserved structural elements: the hydrophobic trough and the C-terminal proteolytic processing site. This finding led us to hypothesize that a conserved structural basis of antigenic escape from anti-AMA-1 exists. Genotyping high-impact AER may be useful for classifying AMA-1 strains into inhibition groups and to detect allelic effects of an AMA-1 vaccine in the field.

Citing Articles

Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.

Ciubotariu I, Broyles B, Xie S, Thimmapuram J, Mwenda M, Mambwe B EBioMedicine. 2024; 106:105227.

PMID: 39018754 PMC: 11663769. DOI: 10.1016/j.ebiom.2024.105227.


Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in .

Ciubotariu I, Broyles B, Xie S, Thimmapuram J, Mwenda M, Mambwe B medRxiv. 2024; .

PMID: 38766239 PMC: 11100930. DOI: 10.1101/2024.05.11.24307175.


High genetic and haplotype diversity in vaccine candidate but not among malaria-infected children in Ibadan, Nigeria.

Oboh M, Asmorom N, Falade C, Ojurongbe O, Thomas B PeerJ. 2023; 11:e16519.

PMID: 38099304 PMC: 10720411. DOI: 10.7717/peerj.16519.


A human antibody epitope map of the malaria vaccine antigen Pfs25.

Shukla N, Tang W, Coelho C, Long C, Healy S, Sagara I NPJ Vaccines. 2023; 8(1):108.

PMID: 37542029 PMC: 10403551. DOI: 10.1038/s41541-023-00712-z.


Symptomatic malaria enhances protection from reinfection with homologous Plasmodium falciparum parasites.

Markwalter C, Petersen J, Zeno E, Sumner K, Freedman E, Mangeni J PLoS Pathog. 2023; 19(6):e1011442.

PMID: 37307293 PMC: 10289385. DOI: 10.1371/journal.ppat.1011442.


References
1.
Polley S, Chokejindachai W, Conway D . Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics. 2003; 165(2):555-61. PMC: 1462796. DOI: 10.1093/genetics/165.2.555. View

2.
Dutta S, Haynes J, Moch J, Barbosa A, Lanar D . Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A. 2003; 100(21):12295-300. PMC: 218752. DOI: 10.1073/pnas.2032858100. View

3.
Pizarro J, Vulliez-Le Normand B, Chesne-Seck M, Collins C, Withers-Martinez C, Hackett F . Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005; 308(5720):408-11. DOI: 10.1126/science.1107449. View

4.
Coley A, Parisi K, Masciantonio R, Hoeck J, Casey J, Murphy V . The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun. 2006; 74(5):2628-36. PMC: 1459722. DOI: 10.1128/IAI.74.5.2628-2636.2006. View

5.
Polhemus M, Magill A, Cummings J, Kester K, Ockenhouse C, Lanar D . Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2007; 25(21):4203-12. DOI: 10.1016/j.vaccine.2007.03.012. View